FIB-4 ≥1.3 is correlated with increased DKD risk in T2D, but SGLT2i therapy that lowers FIB-4 attenuates this . (2025). Diabzen, 3(4), 120-127. https://www.thediabzen.com/index.php/d/article/view/34